New to peptides? Start with the foundations ->
The dad-test answer
Mounjaro and Wegovy are different molecules sold under different brand names. Mounjaro (tirzepatide) is FDA-approved for diabetes; Zepbound is the same molecule for weight loss. Wegovy (semaglutide) is approved for weight loss; Ozempic is the same molecule for diabetes. Mounjaro/Zepbound loses more weight in head-to-head data; Wegovy is cheaper and more available.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| weight loss (off-label or via Zepbound) |
tirzepatide SURMOUNT-5: 20.2% loss on tirzepatide vs 13.7% on Wegovy/semaglutide at 72 weeks. |
| diabetes (Mounjaro vs Ozempic) |
tirzepatide SURPASS-2: stronger A1C drop and stronger weight loss on Mounjaro vs Ozempic at matched doses. |
| insurance coverage / commercial savings card |
semaglutide Wegovy and Ozempic have been on the market longer; broader formulary acceptance in 2026. |
| first-time injectable, sensitive stomach |
semaglutide Lower nausea/vomiting incidence in head-to-head data; longer real-world experience at standard doses. |
What the head-to-head data shows
Mounjaro and Zepbound are both tirzepatide - same molecule, different FDA-approved indication and brand. Wegovy and Ozempic are both semaglutide. The molecule comparison (tirzepatide vs semaglutide) is the substantive question. SURMOUNT-5 head-to-head (NEJM 2025) gave the answer for weight loss: 20.2% tirzepatide vs 13.7% semaglutide. SURPASS-2 (NEJM 2021) gave the answer for diabetes. Zepbound's FDA label (Nov 2023) and the Wegovy label (Jun 2021) cover the approved indications. Branded copay programs change quarterly - check the manufacturer site at decision time.
Our honest call
Don't ask your doctor for the brand - ask for the molecule and the indication. If the goal is weight loss and insurance covers Zepbound, ask for Zepbound. If insurance only covers Wegovy, ask for Wegovy. If the goal is Type 2 diabetes management with weight loss as a bonus, Mounjaro and Ozempic compete head to head and Mounjaro wins on both endpoints. The only reason to default to semaglutide-as-Wegovy/Ozempic in 2026 is access - cheaper, more pharmacies stock it, and more compounding options exist if commercial supply is tight. Read the GLP-1 starter guide before the telehealth call.
Sources and citations
- Aronne et al., SURMOUNT-5 head-to-head trial, NEJM 2025 (PMID 40374016)
- Frias et al., SURPASS-2 trial, NEJM 2021 (PMID 34170647)
- FDA Zepbound prescribing label (approved Nov 2023)
- FDA Mounjaro prescribing label (approved May 2022)
- FDA Wegovy prescribing label (approved Jun 2021)
- FDA Ozempic prescribing label (approved Dec 2017)
Where to go next
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.